Table 1.
Feature | LMWH | Fondaprinux | Idraparinux |
---|---|---|---|
Mode of administration | Subcutaneous | Subcutaneous | Subcutaneous |
Bioavailability | 80–90% | 100% | 100% |
Half-life (h) | 4 | 17 | 80 |
Target | Factor Xa and thrombin | Factor Xa | Factor Xa |
Renal clearance | Yes | Yes | Yes |
Neutralized by protamine sulfate | Partial | No | No |